Cell-Permeable Morpholino Inhibits Programmed Death-Ligand 1 at mRNA Level and Potentiates Antitumor Immunity in Breast Cancer
Sarkar, S.; Ghosh, U.; Pratihar, S.; Sinha, S.
Show abstract
Morpholino-based ASOs with nuclease-resistant backbone and high sequence specificity could modulate the PD-L1/PD-1 axis to overcome T regulatory cell mediated inhibition but poor cell-permeability limits their clinical applications. Here, we develop a guanidinium-modified cell-permeable morpholino specifically targeting PD-L1 in breast cancer. It suppresses PD-L1 expression through effectively mitigating cytokine induced PD-L1 upregulation and enhancing autophagic flux. Notably, the ASO synergistically with durvalumab (anti-PD-L1 antibody) disrupt, hyperglycosylated PD-L1 by mRNA-level interference and also reduced PD-1 T-cell populations. Importantly, systemic and intra-tumoral administration of ASO demonstrated no abnormalities in cardiac tissues which show no off-target toxicity but it reprogrammed the tumor microenvironment by upregulating inducible nitric-oxide synthase and suppressed regulatory cells, collectively enhancing antitumor immune responses. Together, these findings establish morpholino ASO as a promising targeting therapeutic strategy to overcome tumor-induced immunosuppression, opening new avenues for precision treatment in breast-cancer.
Matching journals
The top 16 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Development of 5-FU-modified tumor suppressor microRNAs as a platform for novel microRNA-based cancer therapeutics 94%
- Armored Bicistronic CAR T Cells with Dominant-negative TGF-β Receptor II to Overcome Resistance in Glioblastoma. 94%
- The antitumoral activity of TLR7 ligands is corrupted by the microenvironment of pancreatic tumors 94%
Similar papers in this journal
- siRNA-based Therapeutic Candidate Targeting PRDM2 for Inhibition of Lung Cancer Progression 94%
- Changes in serum CXCL13 levels are associated with outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment 93%
- NRF2 upregulation by CDDO-Me protects AC16 human cardiomyocytes against doxorubicin-induced toxicity. 93%
Similar papers in this journal
- Enabling CAR-T Cell Immunotherapy in Glioblastoma by Modifying Tumor Microenvironment via Oncolytic Adenovirus Encoding Bispecific T Cell Engager 93%
- Enhanced anti-tumor activity by Zinc Finger Repressor-driven epigenetic silencing of immune checkpoints and TGFBR2 in CAR-T cells and TILs 93%
- Targeting MDM2 homodimer and heterodimer disruption with DRx-098D in TP53 wild-type and mutant cancer cells 92%
Similar papers in this journal
- The defined TLR3 agonist, Nexavant, exhibits anti-cancer efficacy and potentiates anti-PD-1 antibody therapy by enhancing immune cell infiltration. 96%
- The epithelial-mesenchymal transcription factor SNAI1 represses transcription of the tumor suppressor miRNA let-7 in cancer 94%
- GABA(A) receptor activation drives GABARAP-Nix mediated autophagy to radiation-sensitize primary and brain-metastatic lung adenocarcinoma tumors 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.